Lets keep the news coming
BioSante Pharmaceuticals, Inc. announced that it has signed an Option
License Agreement with Antex Biologics Inc. for the development of BioSante's calcium phosphate nanoparticle (CAP) platform technology as a
vaccine adjuvant.
Vancouver, BC, Aug. 21, 2000 (Market News Publishing via COMTEX) -- In this collaboration, Antex will test BioSante's proprietary CAP vaccine
adjuvant and delivery system in vaccines against Chlamydia and Helicobacter pylori (H. pylori). BioSante will formulate vaccines using CAP and
Antex proprietary Chlamydia and H. pylori antigens for testing by Antex in animal models. In addition to the research collaboration, BioSante has
granted to Antex an option to a worldwide, non-exclusive license to use BioSante's CAP in Chlamydia and H. pylori vaccines that may be
developed for human use by Antex.
"This agreement with Antex further illustrates our progress in developing CAP as a vaccine adjuvant," said Stephen M. Simes, president and
CEO of BioSante. "We are delighted to be working with Antex and are impressed with their vaccine development program. In addition to Antex,
CAP is in several feasibility studies to determine its efficacy as a vaccine adjuvant with different potential vaccines. We are hopeful that these
studies will result in ongoing vaccine development collaborations."
Chairman and CEO of Antex Vic Esposito remarked: "We are pleased to be testing BioSante's CAP vaccine adjuvant and delivery system
formulated with proprietary Antex vaccines. We are hopeful that these combinations will result in safer and more effective vaccines. Given that
there are no vaccines available for Chlamydia or H. pylori, we are excited about the prospects of this partnering with BioSante."
Chlamydia ("C.") pneumoniae is the third most common cause of epidemic community-acquired pneumonia. Worldwide, 50% of the population
are infected with this organism by the age of 20, and 70-80% are infected by the age of 60. Additionally, C. pneumoniae has recently been
associated with plaques in patients with cardiovascular diseases including atherosclerosis, as well as plaques in the brain associated with
Alzheimer's disease.
H. pylori is a causative agent of gastric ulcers and is responsible for 300,000 new cases, 3.2 million recurrences and approximately 3,200
deaths from duodenal ulcer disease in North America each year. According to the Centers for Disease Control, H. pylori annually causes
gastric ulcers and other related diseases in up to 25 million Americans and infects up to two-thirds of the world's population with other H. pylori
diseases.
As previously reported, results of two BioSante pre-clinical trials indicate that the use of CAP as a vaccine adjuvant and delivery system
enhanced the immunity elicited by CAP/herpes simplex virus (HSV-2) and CAP/influenza M1 protein vaccines. Specifically, the vaccines induced
high levels of IgG2a (Th1 response) and high and sustained mucosal IgA levels. IgE antibody was not detected, nor was any overt local
irritation. Importantly, both vaccines tested elicited protection against challenge with respective lethal doses of live herpes simplex 2 and
influenza.
About Antex Biologics Inc. Antex Biologics is a biopharmaceutical company committed to developing and marketing new products to prevent
and treat infections and related diseases. The Company has three vaccine products in clinical development and has strategic alliances with
SmithKline Beecham, Aventis Pasteur, Pfizer and the U.S. Department of Defense.
About BioSante Pharmaceuticals, Inc. BioSante is an emerging pharmaceutical company developing a pipeline of hormone replacement
products to treat testosterone deficiency in men and estrogen deficiency in women. BioSante also is developing its nanoparticulate- based
platform technology for novel vaccines, vaccine adjuvants and drug delivery systems.
This press release contains forward-looking statements within the meaning of Private Securities Litigation Reform Act of 1995. The statements
regarding BioSante contained in this press release that are not historical in nature, particularly those that utilize terminology such as "may,"
"will," "should," "likely," "expects," "anticipates," "estimates," "believes" or "plans," or comparable terminology, are forward-looking statements
based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially
from those expressed in such forward-looking statements. Important factors known to BioSante that could cause such material differences are
identified and discussed from time to time in BioSante's filings with the Securities and Exchange Commission, including those factors
discussed on pages 12 to 20 of BioSante's Form 10-KSB, which discussion also is incorporated herein by reference.
-0-
TEL: (847) 793-2458 Phillip Donenberg, CFO,
FAX: (847) 793-2457 BioSante Pharmaceuticals, Inc.
Email: donenber@biosantepharma.com
TEL: (416) 815-0700 ext. 233 Joanna Longo, Investor Relations,
FAX: (416) 815-0080 The Equicom Group Inc.
Email: jlongo@equicomgroup.com |
